Story perspectives

Trump Launches Medicare Pilots to Slash Drug Prices

12/24/2025

Center

Trump's Drug Price Initiative

U.S. President Donald Trump announced two Medicare pilot programs to lower prescription drug prices.
The pilots could reduce Medicare spending and beneficiaries’ out-of-pocket costs for drugs.
The measures align with a most-favored nation policy to match prices abroad for U.S. drugs.
The administration secured nine additional drug-manufacturer agreements to support this goal.
The actions mark a continuation of President Donald Trump's efforts to address high drug costs in the United States.

Left

Trump's Price Critique

On December 19, U.S. President Donald Trump criticized U.S. drug prices, blaming foreign governments for lower prices abroad and promising to dramatically cut costs.
Analysts say his claim is flawed, arguing high prices reflect pharmaceutical profits, not foreign subsidies.
Trump's plan would shift costs to allies rather than fix domestic issues.
The approach could strain European and Japanese governments facing pressure from healthcare systems and domestic firms seeking higher prices.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established Medicare Part D, allowing millions of seniors to access prescription drug coverage without enabling Medicare to negotiate prices. This legislation aimed to address rising drug costs, projected at $400 billion over ten years. Recent initiatives by President Trump echo these efforts but risk straining international relations by shifting costs to foreign governments.

1 of 3

Trump's Drug Price Initiative

U.S. President Donald Trump announced two Medicare pilot programs to lower prescription drug prices.
The pilots could reduce Medicare spending and beneficiaries’ out-of-pocket costs for drugs.
The measures align with a most-favored nation policy to match prices abroad for U.S. drugs.
The administration secured nine additional drug-manufacturer agreements to support this goal.
The actions mark a continuation of President Donald Trump's efforts to address high drug costs in the United States.

1 / 3